Roche Amends Boniva Suits Against Teva

Law360, New York (September 25, 2008, 12:00 AM EDT) -- Hoffmann-La Roche Inc. has filed amended complaints in two suits accusing generic-drug maker Teva Pharmaceuticals USA Inc. and Teva division Gate Pharmaceuticals, respectively, of infringing patents related to popular osteoporosis drug Boniva.

The suits were first filed Aug. 12 in U.S. District Court for the District of New Jersey, asserting U.S. Patent Number 7,410,957, which was also issued Aug. 12, and other patents. The '957 patent expires on May 6, 2023.

The complaints also assert U.S. Patent Number 7,192,938, which expires May 6, 2023, and U.S....
To view the full article, register now.